Common Contracts
2 similar null contracts by Atossa Genetics Inc
WARRANT TO PURCHASE COMMON STOCK OF ATOSSA GENETICS, INC.Atossa Genetics Inc • October 4th, 2012 • Surgical & medical instruments & apparatus
THIS WARRANT (the “Warrant”) certifies that, for value received, [●] (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time commencing after the earliest of the following to occur (the “Initial Exercise Date”): (a) six months from the closing of the Company Initial Public Offering (defined below) (b) the closing of a “fundamental transaction” (defined below), or (c) closing of a “significant private financing” (defined below). This Warrant shall expire and no longer be exercisable as of 5:00 p.m. (New York City time) on the fifth anniversary of the Initial Exercise Date (the “Expiration Date”), but not thereafter, and shall entitle the Holder to subscribe for and purchase from Atossa Genetics, Inc., a Delaware corporation (the “Company”), up to [●] shares of the Common Stock of the Company (the “Warrant Shares”) at a purchase price equal to $1.25 per share (the “Exercise Price”). This Warrant has been
WARRANT TO PURCHASE COMMON STOCK OF ATOSSA GENETICS, INC.Atossa Genetics Inc • October 4th, 2012 • Surgical & medical instruments & apparatus
THIS WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time commencing after the earliest of the following to occur (the “Initial Exercise Date”): (a) six months from the closing of the Company Initial Public Offering (defined below) (b) the closing of a “fundamental transaction” (defined below), or (c) closing of a “significant private financing” (defined below). This Warrant shall expire and no longer be exercisable as of 5:00 p.m. (New York City time) on the fifth anniversary of the Initial Exercise Date (the “Expiration Date”), but not thereafter, and shall entitle the Holder to subscribe for and purchase from Atossa Genetics, Inc., a Delaware corporation (the “Company”), up to [CALCULATED AS 100 % OF THE COMMON STOCK ISSUED TO THE INVESTOR PURSUANT TO THE PURCHASE AGREEMENT] shares of the Common Stock of the Company (the “Warrant Shares”
